2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2670

Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Rheumatoid Arthritis: Data from the Espoir Cohort
Abstract Number: 1651

Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Abstract Number: 667

Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Abstract Number: 1545

Comparison of Statin Eligibility According to the Adult Treatment Panel III, ACC/AHA Blood Cholesterol Guideline and Presence of Carotid Plaque By Ultrasound in Hispanics with Rheumatoid Arthritis
Abstract Number: 1414

Comparison of Surgical and Conservative Therapy of Lumbar Disc Herniation with Radicular Signs and Symptoms in a Quality Management Program
Abstract Number: 2402

Comparison of Synovitis on MRI and Pain in Knee Osteoarthritis Patients with and without Chondrocalcinosis: Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 748

Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort
Abstract Number: 660

Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Abstract Number: 438

Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis
Abstract Number: 2746

Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Abstract Number: 736

Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies
Abstract Number: 1996

Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Abstract Number: 1371

Complement-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?
Abstract Number: 2242

Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Abstract Number: 30

Complications of Inflammatory Arthritis in First Nations and Non-First Nations Populations of Alberta, Canada

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].